Dapablix/Dapablix Met

Dapablix contains dapagliflozin, an SGLT2 inhibitor that effectively reduces blood glucose levels by promoting renal glucose excretion. It is indicated for the management of type 2 diabetes mellitus, offering additional benefits such as weight reduction and cardiovascular risk mitigation.
Dapablix Met combines dapagliflozin, an SGLT2 inhibitor, and metformin, a biguanide, to enhance glycemic control in patients with type 2 diabetes. This dual mechanism targets both renal glucose excretion and hepatic glucose production, providing effective blood sugar management. Dapablix Met supports weight reduction and has a proven safety profile, making it a preferred option for comprehensive diabetes care.